Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing
ConclusionsA substantial proportion of men with PCA unselected for metastatic disease carry germline DNA repair PVs. Breast cancer family history and high Gleason score are important predictors to identify men with PCA who may carry germline DNA repair PVs. Our findings support current NCCN guidelines and have implications for genetic assessment, therapeutic management, and cascade testing for men with PCA and their families. (Source: The Prostate)
Source: The Prostate - November 18, 2018 Category: Urology & Nephrology Authors: Veda N. Giri,
Sarah E. Hegarty,
Colette Hyatt,
Erin O'Leary,
John Garcia,
Karen E. Knudsen,
William K. Kelly,
Leonard G. Gomella Tags: ORIGINAL ARTICLE Source Type: research
Death due to sepsis in patients diagnosed with prostate cancer
ConclusionPatients diagnosed with Pca are at increased risk of dying from sepsis, and the sepsis ‐related IBMR in these patients is increasing over time. There are significant disparities in the outcome of sepsis among Pca patients that require further research. (Source: The Prostate)
Source: The Prostate - November 18, 2018 Category: Urology & Nephrology Authors: Shaheen Alanee,
Bradley Holland,
Joseph Clemons,
Danuta Dynda Tags: ORIGINAL ARTICLE Source Type: research
Dual benefit of supplementary oral 5 ‐aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model
ConclusionsOur study provides novel and comprehensive insights into the dual benefits including radiosensitizing PCa tumor tissues and radioprotection of normal pelvic organs from radiation therapy. Knowledge of the underlying mechanism will facilitate the search for optimal treatment parameters for supplemental oral ALA during radiotherapy for PCa. (Source: The Prostate)
Source: The Prostate - November 18, 2018 Category: Urology & Nephrology Authors: Makito Miyake,
Nobumichi Tanaka,
Shunta Hori,
Sayuri Ohnishi,
Hiroo Takahashi,
Tomomi Fujii,
Takuya Owari,
Kenta Ohnishi,
Kota Iida,
Yosuke Morizawa,
Daisuke Gotoh,
Yoshitaka Itami,
Yasushi Nakai,
Takeshi Inoue,
Satoshi Anai,
Kazumasa Torim Tags: ORIGINAL ARTICLE Source Type: research
Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas
ConclusionThe total prevalence of BPH in men aged 40 years or older in Zhengzhou's rural areas was 10.04%, and the heritability of prostatic hyperplasia was 40.48%. (Source: The Prostate)
Source: The Prostate - November 18, 2018 Category: Urology & Nephrology Authors: Limin Yue,
Tao Wang,
Yongchao Ge,
Mengying Ge,
Chengda Zhang,
Quanliang Hou,
Wenhua Wang,
Huizi Tian,
Bingnan Ren,
Binghui Du,
Weidong Zhang Tags: ORIGINAL ARTICLE Source Type: research
Loss of CCAAT ‐enhancer‐binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers
ConclusionsCEBPA is down regulated in about one third of prostate cancers, but the clinical impact of CEBPA loss is strictly limited to the subset of about 10% prostate cancers carrying bothERG fusion and deletions of thePTEN tumor suppressor. Our findings challenge the concept that prognostic molecular markers may be generally applicable to all prostate cancers. (Source: The Prostate)
Source: The Prostate - November 14, 2018 Category: Urology & Nephrology Authors: Sarah Minner,
Jannes Lutz,
Claudia Hube ‐Magg,
Martina Kluth,
Ronald Simon,
Doris Höflmayer,
Eike Burandt,
Maria Christina Tsourlakis,
Guido Sauter,
Franziska Büscheck,
Waldemar Wilczak,
Stefan Steurer,
Thorsten Schlomm,
Hartwig Huland,
Tags: ORIGINAL ARTICLE Source Type: research
Urotensin II receptor expression in prostate cancer patients: A new possible marker
ConclusionUrotensin II receptor is a potential marker of adverse pathological outcomes. Further studies should confirm our data and evaluate its role as a prognostic marker. (Source: The Prostate)
Source: The Prostate - November 8, 2018 Category: Urology & Nephrology Authors: Roberto Giulianelli,
Stefano Nardoni,
Dario Bruzzese,
Cristina Falavolti,
Gabriella Mirabile,
Mariangela Bellangino,
Giorgia Tema,
Barbara Cristina Gentile,
Luca Albanesi,
Maurizio Buscarini,
Paola Tariciotti,
Riccardo Lombardo Tags: ORIGINAL ARTICLE Source Type: research
Issue Information ‐ Editorial Board
The Prostate,Volume 78, Issue 16, Page 1213-1213, December 1, 2018. (Source: The Prostate)
Source: The Prostate - November 2, 2018 Category: Urology & Nephrology Source Type: research
Tumor cell heterogeneity and resistance; report from the 2018 Coffey ‐Holden Prostate Cancer Academy Meeting
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - November 1, 2018 Category: Urology & Nephrology Authors: Andrea K. Miyahira,
Robert B. Den,
Maria I. Carlo,
Ren ée de Leeuw,
Thomas A. Hope,
Fatima Karzai,
Rana R. McKay,
Simpa S. Salami,
Jonathan W. Simons,
Kenneth J. Pienta,
Howard R. Soule Source Type: research
Sex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial)
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - October 29, 2018 Category: Urology & Nephrology Authors: Matthias E. Meunier,
Yann Neuzillet,
Jean ‐Pierre Raynaud,
Camelia Radulescu,
Tarek Ghoneim,
Jean Fiet,
Franck Giton,
Mathieu Rouanne,
Jean‐François Dreyfus,
Thierry Lebret,
Henry Botto Source Type: research
Clinical effectiveness of docetaxel for castration ‐sensitive prostate cancer in a real‐world population‐based analysis
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - October 29, 2018 Category: Urology & Nephrology Authors: Jean ‐Michel Lavoie,
Kevin Zou,
Daniel Khalaf,
Bernhard J. Eigl,
Christian K. Kollmannsberger,
Joanna Vergidis,
Krista Noonan,
Muhammad Zulfiqar,
Daygen Finch,
Kim N. Chi Source Type: research
Tyrosine kinase inhibitor therapy prescribed for non ‐urologic diseases can modify PSA titers in urology patients
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - October 29, 2018 Category: Urology & Nephrology Authors: Takeshi Sasaki,
Omar E. Franco,
Kohshi Ohishi,
Yana Filipovich,
Kenichiro Ishii,
Susan E. Crawford,
Naoto Takahashi,
Naoyuki Katayama,
Yoshiki Sugimura,
Simon W. Hayward Source Type: research
Combined N ‐terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - October 22, 2018 Category: Urology & Nephrology Authors: Benedikt Kranzb ühler,
Souzan Salemi,
Ashkan Mortezavi,
Tullio Sulser,
Daniel Eberli Source Type: research
MicroRNAs as prognostic markers in prostate cancer
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - October 22, 2018 Category: Urology & Nephrology Authors: Ilknur Suer,
Esra Guzel,
Omer F. Karatas,
Chad J. Creighton,
Michael Ittmann,
Mustafa Ozen Source Type: research
A role for paracrine interleukin ‐6 signaling in the tumor microenvironment in prostate tumor growth
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - October 22, 2018 Category: Urology & Nephrology Authors: Shu ‐Han Yu,
Janielle P. Maynard,
Ajay M. Vaghasia,
Angelo M. De Marzo,
Charles G. Drake,
Karen S. Sfanos Source Type: research
Lack of combination effects of soy isoflavones and taxane chemotherapy of castration ‐resistant prostate cancer
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - October 22, 2018 Category: Urology & Nephrology Authors: Jillian N. Eskra,
Michael J. Schlicht,
Maarten C. Bosland Source Type: research
